Recombinant erythropoietin treatment improves serum podocyte marker levels in diabetic kidney disease
Background: Recombinant human erythropoietin (rHuEPO) is an effective treatment for renal anemia. Recently, there is evidence to suggest that rHuEPO may reduce podocyte injury in diabetic kidney disease (DKD). However, there is no published study on the change in podocyte injury marker levels before...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co. Ltd.
2023-01-01
|
| Series: | Advances in Biomarker Sciences and Technology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2543106423000066 |